Could aducanumab be the first drug to slow Alzheimer’s disease?

The biotechnology company Biogen along with Japanese pharmaceutical company applied for a Biologics License Application with the U.S. Food and Drug Administration for regulatory approval of aducanumab.  Aducanumab is an investigational biologic medication for early Alzheimer’s disease to slow the clinical progression of the disease.  The FDA was given 60 days to decide whether the application was granted Priority Review status upon acceptance. Read article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org